Sangui Biotech International (SGBI) 10-Q 16 May 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Mar. 31, 2022	May 16, 2022
Details
Registrant CIK	0001104280
Fiscal Year End	--06-30
Registrant Name	SANGUI BIOTECH INTERNATIONAL INC
SEC Form	10-Q
Period End date	Mar. 31, 2022
Tax Identification Number (TIN)	84-1330732
Number of common stock shares outstanding		209,901,842
Filer Category	Non-accelerated Filer
Current with reporting	Yes
Interactive Data Current	Yes
Shell Company	false
Small Business	true
Emerging Growth Company	false
Document Quarterly Report	true
Entity File Number	0-21271
Entity Incorporation, State or Country Code	CO
Entity Address, Address Line One	Bleichenbrücke 9
Entity Address, Postal Zip Code	20354
Entity Address, City or Town	Hamburg
Entity Address, Country	DE
Country Region	49
City Area Code	40
Local Phone Number	46093120
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Document Transition Report	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2022	Jun. 30, 2021
CURRENT ASSETS
Cash	$ 67,617	$ 29,768
Prepaid expenses and other assets	17,649	12,020
Tax refunds receivable	312	2,286
Accounts receivable, net	21,616	16,631
Note receivable, related party	7,599	5,961
Total Current Assets	114,793	66,666
Property and equipment, net	567	1,215
Operating lease right-of-use asset	71,213	66,241
TOTAL ASSETS	186,573	134,122
LIABILITIES
Accounts payable and accrued expenses	128,562	127,311
Accrued interest - related party	71,928	62,485
Current portion of Note payable	11,755	0
Notes payable - related party	747,114	752,508
Other Current Liabilities	0	0
Current portion of operating lease liability	16,646	12,403
Total Current Liabilities	976,005	954,707
Operating lease liability, net of current portion	47,743	54,740
Note payable, net of current portion	54,734	0
Total longterm Liabilities	102,477	54,740
Total Liabilities	1,078,482	1,009,447
STOCKHOLDERS' DEFICIT
Preferred stock, no par value; 10,000,000 shares authorized, -0- shares issued and outstanding	0	0
Common stock, no par value; 250,000,000 shares authorized 209,955,598 and 206,955,598 shares issued and 209,901,842 and 206,901,842 shares outstanding respectively	33,124,956	33,088,176
Additional paid-in capital	4,513,328	4,513,328
Treasury stock, at cost	(19,387)	(19,387)
Accumulated other comprehensive income	89,860	89,670
Accumulated deficit	(37,947,171)	(37,895,315)
Total stockholders' deficit	(238,414)	(223,528)
Non-controlling interest	(653,495)	(651,797)
Total Stockholders' Deficit	(891,909)	(875,325)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 186,573	$ 134,122

Consolidated Balance Sheets - P

Consolidated Balance Sheets - Parenthetical - shares	Mar. 31, 2022	Jun. 30, 2021
Details
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Shares Authorized	250,000,000	250,000,000
Common Stock, Shares, Issued	209,955,598	206,955,598
Common Stock, Shares, Outstanding	209,901,842	206,901,842

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
REVENUES
License revenues	$ 17,954	$ 21,182	$ 58,686	$ 51,754
GROSS MARGIN	17,954	21,182	58,686	51,754
OPERATING EXPENSES
Research and development	1,979	2,060	6,478	6,482
Professional fees	32,312	32,911	104,921	117,750
General and administrative	11,921	14,330	38,393	37,951
Depreciation and amortization	192	206	589	610
Total Operating Expenses	46,404	49,507	150,381	162,793
OPERATING LOSS	(28,450)	(28,325)	(91,695)	(111,039)
OTHER INCOME (EXPENSE)
Gain (Loss) on foreign exchange	21,790	32,167	56,376	(27,611)
Interest expense	(4,562)	(4,580)	(13,981)	(13,273)
Loss on Settlement on accounts payable	(4,254)	0	(4,254)	0
Total other income (expense)	12,974	27,587	38,141	(40,884)
LOSS BEFORE INCOME TAXES AND NON-CONTROLLING INTEREST	(15,476)	(738)	(53,554)	(151,923)
Provision for income taxes	0	0	0	0
NET LOSS BEFORE NON-CONTROLLING INTEREST	(15,476)	(738)	(53,554)	(151,923)
Less: Net loss attributable to non-controlling interest	614	648	1,698	3,057
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	(14,862)	(90)	(51,856)	(148,866)
OTHER COMPREHENSIVE LOSS
Foreign currency translation adjustments	1,123	(287)	190	(1,453)
COMPREHENSIVE LOSS	$ (14,353)	$ (1,025)	$ (53,364)	$ (153,376)
BASIC AND DILUTED LOSS PER SHARE	$ 0	$ 0	$ 0	$ 0
BASIC AND DILUTED WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING	209,323,453	203,355,598	208,284,597	203,355,598

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit - USD ($)	Common Stock	Additional Paid-in Capital	Treasury Stock	AOCI Including Portion Attributable to Noncontrolling Interest	Noncontrolling Interest	Retained Earnings	Total
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Jun. 30, 2020	$ 33,027,676	$ 4,513,328	$ (19,387)	$ 91,907	$ (646,977)	$ (37,696,425)	$ (729,878)
Shares, Outstanding, Beginning Balance at Jun. 30, 2020	203,355,598
Proceeds from common stock issued for cash							0
Currency translation adjustment	$ 0	0	0	(1,453)	0	0	(1,453)
Net loss	0	0	0	0	(3,057)	(148,866)	(151,923)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Mar. 31, 2021	$ 33,027,676	4,513,328	(19,387)	90,454	(650,034)	(37,845,291)	(883,254)
Shares, Outstanding, Ending Balance at Mar. 31, 2021	203,355,598
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2020	$ 33,027,676	4,513,328	(19,387)	90,741	(649,386)	(37,845,201)	(882,229)
Shares, Outstanding, Beginning Balance at Dec. 31, 2020	203,355,598
Currency translation adjustment	$ 0	0	0	(287)	0	0	(287)
Net loss	0	0	0	0	(648)	(90)	(738)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Mar. 31, 2021	$ 33,027,676	4,513,328	(19,387)	90,454	(650,034)	(37,845,291)	(883,254)
Shares, Outstanding, Ending Balance at Mar. 31, 2021	203,355,598
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Jun. 30, 2021	$ 33,088,176	4,513,328	(19,387)	89,670	(651,797)	(37,895,315)	(875,325)
Shares, Outstanding, Beginning Balance at Jun. 30, 2021	206,955,598
Proceeds from common stock issued for cash	$ 28,345	0	0	0	0	0	28,345
Common stock issued for cash	2,616,556
Common stock issued to settle accounts payable	$ 8,435	0	0	0	0	0	$ 8,435
Common stock issued to settle accounts payable	383,444						383,444
Currency translation adjustment	$ 0	0	0	190	0	0	$ 190
Net loss	0	0	0	0	(1,698)	(51,856)	(53,554)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Mar. 31, 2022	$ 33,124,956	4,513,328	(19,387)	89,860	(653,495)	(37,947,171)	(891,909)
Shares, Outstanding, Ending Balance at Mar. 31, 2022	209,955,598
Common stock issued for services	$ 0	0	0	0	0	0	0
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2021	$ 33,100,043	4,513,328	(19,387)	88,737	(652,881)	(37,932,309)	(902,469)
Shares, Outstanding, Beginning Balance at Dec. 31, 2021	207,955,598
Proceeds from common stock issued for cash	$ 16,478	0	0	0	0	0	16,478
Common stock issued for cash	1,616,556
Common stock issued to settle accounts payable	$ 8,435	0	0	0	0	0	8,435
Common stock issued to settle accounts payable	383,444
Currency translation adjustment	$ 0	0	0	1,123	0	0	1,123
Net loss	0	0	0	0	(614)	(14,862)	(15,476)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Mar. 31, 2022	$ 33,124,956	$ 4,513,328	$ (19,387)	$ 89,860	$ (653,495)	$ (37,947,171)	$ (891,909)
Shares, Outstanding, Ending Balance at Mar. 31, 2022	209,955,598

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (53,554)	$ (151,923)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation and amortization	589	610
Foreign currency exchange transactions	(55,573)	27,611
Loss on settlement of debt	4,182	0
Amortization of right to use asset	(13,436)	(16,009)
Changes in operating assets and liabilities
Trade accounts receivable	(6,282)	(15,518)
Prepaid expenses and other current assets	(16,767)	(5,193)
Tax refunds receivable	1,890	6,660
Accounts payable and accrued expenses	10,016	15,604
Related party advances	(2,097)	5,665
Related party accounts payable	11,872	11,852
Operating lease liability	16,041	16,463
Net Cash Used in Operating Activities	(103,119)	(104,178)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from related party note payable	46,445	101,515
Proceeds from common stock issued for cash	28,345	0
Proceeds from note payable	68,865	0
Net Cash Provided by Financing Activities	143,655	101,515
EFFECTS OF EXCHANGE RATES ON CASH	(2,687)	(999)
NET CHANGES IN CASH	37,849	(3,662)
CASH AT BEGINNING OF PERIOD	29,768	15,282
CASH AT END OF PERIOD	67,617	11,620
NON - CASH INVESTING AND FINANCING ACTIVITIES
Initial Right of use operating lease assets	24,110	0
Initial Right of operating liabilities	13,563	0
Common Stock issued for settle accounts payables	$ 8,436	$ 0

NOTE 1 - BASIS OF PRESENTATION

NOTE 1 - BASIS OF PRESENTATION	9 Months Ended
	Mar. 31, 2022
Notes
NOTE 1 - BASIS OF PRESENTATION	NOTE 1 - BASIS OF PRESENTATION The accompanying condensed consolidated financial statements have been prepared without audit in accordance with accounting principles generally accepted in the United States of America and rules of the Securities Exchange Commission for interim financial information. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. The unaudited condensed consolidated financial statements and notes should, therefore, be read in conjunction with the consolidated financial statements and notes thereto in the Company's Form 10-K for the year ended June 30, 2021. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair presentation, have been included. The results of operations for the nine-month period ended March 31, 2022 are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2022. In December 2019, COVID-19 emerged and has subsequently spread worldwide. The World Health Organization has declared COVID-19 a pandemic resulting in federal, state and local governments and private entities mandating various restrictions, including travel restrictions, restrictions on public gatherings, stay at home orders and advisories and quarantining of people who may have been exposed to the virus. At the present time, it is not clear how long this crisis will last and what extent it will take. The highest priority for the Company is the health of employees and business partners. The Company’s main product is affected by the restrictions currently in place around the world. The global restrictions drastically limit our sales activities. Therefore, the license revenue the Company anticipated is not, and for the foreseeable future, will not be received at the levels as planned. The Company is in close contact with its licensee who is responsible for all distribution. Both the Company and its licensee assume that the desired growth of sales will be resumed after the pandemic has been overcome and restrictions are lessened. Prior to the pandemic, the Company had essentially been financed through the sale of shares or by loans from related parties. These financing options are still available to the Company during the COVID-19 crisis.

NOTE 2 - SUMMARY OF SIGNIFICANT

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Mar. 31, 2022
Notes
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization and Nature of Business Sangui Biotech International, Inc., (Sangui or the Company) was incorporated in Colorado in 1995 and conducts business through its 90% owned subsidiary, Sangui BioTech GmbH (Sangui GmbH) and its 99.8% owned subsidiary Sangui Know-how und Patentverwertungsgesellschaft mbH & Co. KG (Sangui KG). Sangui GmbH, which is headquartered in Hamburg, Germany, is engaged in the development of artificial oxygen carriers (external applications of hemoglobin, blood substitutes and blood additives) as well as in the development, marketing and sales of cosmetics and wound management products. Sangui KG is a limited partnership that holds the license rights under the various agreements that the Company enters into from time to time. Principles of Consolidation The consolidated financial statements include the accounts of the Company, Sangui BioTech GmbH and Sangui KG. All intercompany accounts and transactions have been eliminated in consolidation Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the respective reporting period. As future events and their effects cannot be determined with precision, actual results could differ from those estimates. Significant estimates made by management are, among others, the realization of receivables, inventories, long-lived assets, and valuation allowance on deferred tax assets. Due to the current dependence of Sangui on the revenue from the license agreement with Mölnlycke Health Care GmbH, management places the highest priority on the sales development in this area in order to be able to recognize potential risks in good time and to take appropriate measures if necessary. These measures include regular and ad hoc discussions with the licensee about its planned business development. Foreign Currency Translation Assets and liabilities of the Company's foreign operations are translated into U.S. dollars at period-end exchange rates. Net exchange gains or losses resulting from such translation are excluded from net loss but are included in comprehensive loss and accumulated in a separate component of stockholders' equity (deficit). Income and expenses are translated at average exchange rates for the period. Exchanges rates used for the preparation of the consolidated balance sheet as of March 31, 2022 and June 30, 2021 and our unaudited consolidated statements of operations for the nine-month periods ended March 31, 2022 and 2021, were calculated as follows: as of March 31, 2022 0.902405 as of March 31, 2021 0.851250 July 1, 2021 through March 31, 2022 0.871273 July 1, 2020 through March 31, 2021 0.841351 The Company accounts for the transactions denominated in foreign currencies in the Parent Company’s books as transaction gains (losses) recognized in Other Income. Going Concern The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has accumulated deficit of $37,947,171 as of March 31, 2022. The Company incurred a net loss before non-controlling interest of $53,554 for the nine-months ended March 31, 2022 and used cash in operating activities of $103,119 during the same nine-months ended March 31, 2022. These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from issuance of the financial statements. The Company expects to continue to incur significant capital expenses in pursuing its business plan to market its products and expand its product line, while obtaining additional financing through stock offerings or other feasible financing alternatives. In order for the Company to continue its operations at its existing levels, the Company will require significant additional funds over the next twelve months. Therefore, the Company is dependent on funds raised through equity or debt offerings. Additional financing may not be available on terms favorable to the Company, or at all. If these funds are not available, the Company may not be able to execute its business plan or take advantage of business opportunities. The ability of the Company to obtain such additional financing and to achieve its operating goals is uncertain. In the event that the Company does not obtain additional capital, is not able to collect its outstanding receivables, or is not able to increase cash flow through the increase of sales, there is a substantial doubt of its being able to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Cash and Cash Equivalents The Company maintains its cash in bank accounts in Germany. Cash and cash equivalents include time deposits for which the Company has no requirements for compensating balances. The Company has not experienced any losses in its uninsured bank accounts. Research and Development Research and development costs are charged to operations as they are incurred. Legal fees and other direct costs incurred in obtaining and protecting patents are expensed as incurred. Revenue Recognition In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The new revenue recognition standard provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied. Type of Revenue The Company derives revenue primarily from licensing fees on sales of its wound spray product. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic ASC 606 set forth below. The Company’s licenses provide a right to use and create performance obligations satisfied at a point in time. The Company recognizes revenue from the license when the performance obligation is satisfied through the transfer of the license. The Company will recognize royalty revenue a) when the licensee makes the subsequent sales or use that trigger the royalty, or (b) the performance obligation to which Trade Accounts Receivable Accounts receivable are reflected at estimated net realizable value. The Company maintains an allowance for doubtful accounts based upon a variety of factors. The Company reviews all open accounts and provides specific reserves for customer collection issues when it believes a loss is probable. The reserve estimate includes consideration of such factors as the length of time receivables are past due, the financial condition of the customer, and historical experience. The Company also records a reserve for all customers, excluding those that have been specifically reserved for, based upon evaluation of historical losses which exceeded the specific reserves the Company had established. For the year ended June 30, 2021 and for the nine-month period ended March 31, 2022, the Company recognized bad debt expense in the amounts of $0 and $0, respectively. Basic and Diluted Earnings (Loss) Per Common Share Basic earnings (loss) per common share are computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted earnings (loss) per share give effect to all potential dilutive common shares outstanding during the period of compensation. The computation of diluted earnings (loss) per share does not assume conversion, exercise or contingent exercise of securities that would have an antidilutive effect on earnings. As of March 31, 2022, the Company had no potentially dilutive securities that would affect the loss per share if they were to be dilutive. Comprehensive Loss Total comprehensive loss represents the net change in stockholders' equity (deficit) during a period from sources other than transactions with stockholders and as such, includes net earnings (loss). For the Company, the components of other comprehensive loss are limited to the changes in the cumulative foreign currency translation adjustments, which is recorded as components of stockholders' equity (deficit). Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying consolidated financial statements.

NOTE 3 - COMMITMENTS AND CONTIN

NOTE 3 - COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Mar. 31, 2022
Notes
NOTE 3 - COMMITMENTS AND CONTINGENCIES	NOTE 3 - COMMITMENTS AND CONTINGENCIES Litigation The Company may, from time to time, be involved in various legal disputes resulting from the ordinary course of operating its business. Management is currently not able to predict the outcome of any such cases. However, management believes that the amount of ultimate liability, if any, with respect to such actions will not have a material effect on the Company's financial position or results of operations. At the time of reporting, no litigation is pending. Indemnities and Guarantees During the normal course of business, the Company has made certain indemnities and guarantees under which it may be required to make payments in relation to certain transactions. These indemnities include certain agreements with the Company's officers, under which the Company may be required to indemnify such person for liabilities arising out of their employment relationship. The duration of these indemnities and guarantees varies and, in certain cases, is indefinite. The majority of these indemnities and guarantees do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not been obligated to make significant payments for these obligations and no liabilities have been recorded for these indemnities and guarantees in the accompanying consolidated balance sheet. Leases The Company leases office facilities from an unrelated third party at 1,172 Euros per month, which amount includes 187 Euros for sales tax. The office lease contract began in January 2020 and expires June 2026. The Company also leases an automobile under an operating lease. The lease provides for a lease payment of 538 Euros per month that began June 2018 expired May of 2020. The company extended the expired contract until May 2021 and then continued on a month-to-month basis, until a new lease vehicle was available. The monthly leasing rate was 670 Euros for the period from June 2020 to May 2021. The company has signed a leasing contract for a new automobile with a term of 36 months with monthly leasing installments of 338 Euros ($375) and an initial deposit of 9,189 Euros ($10,183) in May 2021. The automobile was delivered in August 2021. The leasing contract that expired in May 2021 was continued until the new automobile has been delivered. The following table reconciles future minimum operating lease payments to the discounted lease liability as of March 31, 2022: Minimum Lease Payments Under Operating Leases Office Automotive Total Year ending June 30, 2022 3,216 1,125 4,341 2023 12,978 4,501 17,479 2024 13,211 4,501 17,712 Thereafter 27,141 375 27,516 Total Operating Lease Obligations $ 56,546 10,502 $ 67,048 Less: Amount representing imputed interest $ (2,409) (250) $ (2,659) Present Value of minimum lease payments $ 54,137 10,252 $ 64,389 Weighted average discount rate 2% Weighted average remaining term 3.94 years License Agreement Pursuant to the contracts dated May 2, 2018 and November 11, 2018 between Sangui GmbH and Sangui KG, respectively, and a former contractor, Sangui KG grants that contractor a license fee on the license income received by Sangui for his previous services as a co-inventor. The license fee is 10% analogously to the remuneration regulation of the German Law on Employee Inventions (ArbnErfG

NOTE 4 - RELATED PARTY TRANSACT

NOTE 4 - RELATED PARTY TRANSACTIONS	9 Months Ended
	Mar. 31, 2022
Notes
NOTE 4 - RELATED PARTY TRANSACTIONS	NOTE 4 – DEBT Notes Payable Related Parties As of March 31, 2022, the Company had outstanding the following loans payable due to a Company Director: Date Loan amount in EURO Loan amount converted into USD Interest rate Interest in USD Due March 06, 2015 100,000 110,815 5% 38,202 June 30, 2022 December 12, 2017 25,000 27,704 2% 2,383 on demand January 19, 2018 25,000 27,704 2% 2,326 on demand March 13, 2018 25,000 27,704 2% 2,245 on demand July 16, 2018 25,000 27,704 2% 2,055 on demand September 10, 2018 25,000 27,704 2% 1,970 on demand October 04, 2018 25,000 27,704 2% 1,934 on demand December 27, 2018 25,000 27,704 2% 1,806 on demand January 21, 2019 15,000 16,622 2% 1,061 on demand February 26, 2019 25,000 27,704 2% 1,714 on demand March 20, 2019 25,000 27,704 2% 1,680 on demand April 08, 2019 20,000 22,163 2% 1,321 on demand May 09, 2019 30,000 33,245 2% 1,925 on demand June 21, 2019 30,000 33,245 2% 1,847 on demand September 17, 2019 20,000 22,163 2% 1,125 on demand October 04, 2019 20,000 22,163 2% 1,104 on demand October 30, 2019 20,000 22,163 2% 1,072 on demand January 08, 2020 10,000 11,082 2% 494 on demand February 20, 2020 10,000 11,082 2% 468 on demand March 06, 2020 15,000 16,622 2% 688 on demand April 01, 2020 10,000 11,082 2% 443 on demand May 05, 2020 15,000 16,622 2% 633 on demand June 10, 2020 10,000 11,082 2% 400 on demand July 27, 2020 10,000 11,082 2% 372 on demand September 07, 2020 10,000 11,114 2% 346 on demand September 21, 2020 10,000 11,193 2% 338 on demand October 09, 2020 15,000 16,659 2% 490 on demand December 03, 2020 10,000 10,784 2% 293 on demand January 05, 2021 10,000 10,638 2% 273 on demand February 11, 2021 10,000 10,806 2% 251 on demand March 17, 2021 10,000 11,029 2% 230 on demand July 29, 2021 10,000 11,082 2% 149 on demand October 04, 2021 20,000 22,163 2% 216 on demand December 01, 2021 10,000 11,082 2% 73 on demand Total 675,000 747,114 71,928 On July 29, 2021, October 04, 2021, and December 01, 2021 a Company Director advanced amounts totaling 40,000 Euros ($44,326 as of March 31, 2022) to the Company. The loans are due on demand, accrue interest annually at 2% and are unsecured. As of March 31, 2022, all notes issued have total interest accrued of $71,928. Interest expense for the nine-month period ended March 31, 2022 and 2021 was $13,981 and $13,273, respectively. Notes payable On March 25, 2022, the Company entered into a note for 60,000 Euros ($66,489) and accrues interest annually at 6.0%. Interest and principal will be repaid in 60 equal monthly installments of 1,160 Euros starting at the end of April 2022. The last installment is due on March 31, 2027. The loan is secured by the assignment of future receivables from the license agreement relating to the wound spray.

NOTE 5 - CAPITAL STOCK

NOTE 5 - CAPITAL STOCK	9 Months Ended
	Mar. 31, 2022
Notes
NOTE 5 - CAPITAL STOCK	NOTE 5 – STOCKHOLDERS’ DEFICT Preferred Stock Common Stock During the nine-months ended March 31, 2022, the Company sold 1,000,000 shares of its common stock for approximately $11,867 in cash proceeds to one individual at price of approximately $0.0119 per share. The Company sold 1,616,556 shares of its common stock for approximately $16,478 in cash proceeds to one individual at price of approximately $ 0.0102 per share. It was also agreed with the same individual to settle a liability of the company of $8,435 by issuing 383,444 shares of its common stock. This resulted in a loss on settlement of accounts payable of $4,254, which was charged to shareholders' equity. Treasury Stock

NOTE 6 - SUBSEQUENT EVENTS

NOTE 6 - SUBSEQUENT EVENTS	9 Months Ended
	Mar. 31, 2022
Notes
NOTE 6 - SUBSEQUENT EVENTS	NOTE 6 – SUBSEQUENT EVENTS In accordance with ASC 855-10, the Company’s management has reviewed all material events and there are no additional material subsequent events to report.

NOTE 2 - SUMMARY OF SIGNIFICA_2

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Principles of Consolidation (Policies)	9 Months Ended
	Mar. 31, 2022
Policies
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company, Sangui BioTech GmbH and Sangui KG. All intercompany accounts and transactions have been eliminated in consolidation

NOTE 2 - SUMMARY OF SIGNIFICA_3

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Use of Estimates (Policies)	9 Months Ended
	Mar. 31, 2022
Policies
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the respective reporting period. As future events and their effects cannot be determined with precision, actual results could differ from those estimates. Significant estimates made by management are, among others, the realization of receivables, inventories, long-lived assets, and valuation allowance on deferred tax assets. Due to the current dependence of Sangui on the revenue from the license agreement with Mölnlycke Health Care GmbH, management places the highest priority on the sales development in this area in order to be able to recognize potential risks in good time and to take appropriate measures if necessary. These measures include regular and ad hoc discussions with the licensee about its planned business development.

NOTE 2 - SUMMARY OF SIGNIFICA_4

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Foreign Currency Translation (Policies)	9 Months Ended
	Mar. 31, 2022
Policies
Foreign Currency Translation	Foreign Currency Translation Assets and liabilities of the Company's foreign operations are translated into U.S. dollars at period-end exchange rates. Net exchange gains or losses resulting from such translation are excluded from net loss but are included in comprehensive loss and accumulated in a separate component of stockholders' equity (deficit). Income and expenses are translated at average exchange rates for the period. Exchanges rates used for the preparation of the consolidated balance sheet as of March 31, 2022 and June 30, 2021 and our unaudited consolidated statements of operations for the nine-month periods ended March 31, 2022 and 2021, were calculated as follows: as of March 31, 2022 0.902405 as of March 31, 2021 0.851250 July 1, 2021 through March 31, 2022 0.871273 July 1, 2020 through March 31, 2021 0.841351 The Company accounts for the transactions denominated in foreign currencies in the Parent Company’s books as transaction gains (losses) recognized in Other Income.

NOTE 2 - SUMMARY OF SIGNIFICA_5

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Going Concern (Policies)	9 Months Ended
	Mar. 31, 2022
Policies
Going Concern	Going Concern The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has accumulated deficit of $37,947,171 as of March 31, 2022. The Company incurred a net loss before non-controlling interest of $53,554 for the nine-months ended March 31, 2022 and used cash in operating activities of $103,119 during the same nine-months ended March 31, 2022. These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from issuance of the financial statements. The Company expects to continue to incur significant capital expenses in pursuing its business plan to market its products and expand its product line, while obtaining additional financing through stock offerings or other feasible financing alternatives. In order for the Company to continue its operations at its existing levels, the Company will require significant additional funds over the next twelve months. Therefore, the Company is dependent on funds raised through equity or debt offerings. Additional financing may not be available on terms favorable to the Company, or at all. If these funds are not available, the Company may not be able to execute its business plan or take advantage of business opportunities. The ability of the Company to obtain such additional financing and to achieve its operating goals is uncertain. In the event that the Company does not obtain additional capital, is not able to collect its outstanding receivables, or is not able to increase cash flow through the increase of sales, there is a substantial doubt of its being able to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

NOTE 2 - SUMMARY OF SIGNIFICA_6

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Cash and Cash Equivalents (Policies)	9 Months Ended
	Mar. 31, 2022
Policies
Cash and Cash Equivalents	Cash and Cash Equivalents The Company maintains its cash in bank accounts in Germany. Cash and cash equivalents include time deposits for which the Company has no requirements for compensating balances. The Company has not experienced any losses in its uninsured bank accounts.

NOTE 2 - SUMMARY OF SIGNIFICA_7

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Research and Development (Policies)	9 Months Ended
	Mar. 31, 2022
Policies
Research and Development	Research and Development Research and development costs are charged to operations as they are incurred. Legal fees and other direct costs incurred in obtaining and protecting patents are expensed as incurred.

NOTE 2 - SUMMARY OF SIGNIFICA_8

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Revenue Recognition (Policies)	9 Months Ended
	Mar. 31, 2022
Policies
Revenue Recognition	Revenue Recognition In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The new revenue recognition standard provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied. Type of Revenue The Company derives revenue primarily from licensing fees on sales of its wound spray product. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic ASC 606 set forth below. The Company’s licenses provide a right to use and create performance obligations satisfied at a point in time. The Company recognizes revenue from the license when the performance obligation is satisfied through the transfer of the license. The Company will recognize royalty revenue a) when the licensee makes the subsequent sales or use that trigger the royalty, or (b) the performance obligation to which

NOTE 2 - SUMMARY OF SIGNIFICA_9

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Trade Accounts Receivable (Policies)	9 Months Ended
	Mar. 31, 2022
Policies
Trade Accounts Receivable	Trade Accounts Receivable Accounts receivable are reflected at estimated net realizable value. The Company maintains an allowance for doubtful accounts based upon a variety of factors. The Company reviews all open accounts and provides specific reserves for customer collection issues when it believes a loss is probable. The reserve estimate includes consideration of such factors as the length of time receivables are past due, the financial condition of the customer, and historical experience. The Company also records a reserve for all customers, excluding those that have been specifically reserved for, based upon evaluation of historical losses which exceeded the specific reserves the Company had established. For the year ended June 30, 2021 and for the nine-month period ended March 31, 2022, the Company recognized bad debt expense in the amounts of $0 and $0, respectively.

NOTE 2 - SUMMARY OF SIGNIFIC_10

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Basic and Diluted Loss per Common Share (Policies)	9 Months Ended
	Mar. 31, 2022
Policies
Basic and Diluted Loss per Common Share	Basic and Diluted Earnings (Loss) Per Common Share Basic earnings (loss) per common share are computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted earnings (loss) per share give effect to all potential dilutive common shares outstanding during the period of compensation. The computation of diluted earnings (loss) per share does not assume conversion, exercise or contingent exercise of securities that would have an antidilutive effect on earnings. As of March 31, 2022, the Company had no potentially dilutive securities that would affect the loss per share if they were to be dilutive.

NOTE 2 - SUMMARY OF SIGNIFIC_11

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Comprehensive Loss (Policies)	9 Months Ended
	Mar. 31, 2022
Policies
Comprehensive Loss	Comprehensive Loss Total comprehensive loss represents the net change in stockholders' equity (deficit) during a period from sources other than transactions with stockholders and as such, includes net earnings (loss). For the Company, the components of other comprehensive loss are limited to the changes in the cumulative foreign currency translation adjustments, which is recorded as components of stockholders' equity (deficit).

NOTE 2 - SUMMARY OF SIGNIFIC_12

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Segments of an Enterprise and Related Information (Policies)	9 Months Ended
	Mar. 31, 2022
Policies
Segments of an Enterprise and Related Information	Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying consolidated financial statements.

NOTE 2 - SUMMARY OF SIGNIFIC_13

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Foreign Currency Translation: Schedule of Foreign currency rates (Tables)	9 Months Ended
	Mar. 31, 2022
Tables/Schedules
Schedule of Foreign currency rates	as of March 31, 2022 0.902405 as of March 31, 2021 0.851250 July 1, 2021 through March 31, 2022 0.871273 July 1, 2020 through March 31, 2021 0.841351

NOTE 3 - COMMITMENTS AND CONT_2

NOTE 3 - COMMITMENTS AND CONTINGENCIES: Minimum Lease Payments Under Operating Leases (Tables)	9 Months Ended
	Mar. 31, 2022
Tables/Schedules
Minimum Lease Payments Under Operating Leases	The following table reconciles future minimum operating lease payments to the discounted lease liability as of March 31, 2022: Minimum Lease Payments Under Operating Leases Office Automotive Total Year ending June 30, 2022 3,216 1,125 4,341 2023 12,978 4,501 17,479 2024 13,211 4,501 17,712 Thereafter 27,141 375 27,516 Total Operating Lease Obligations $ 56,546 10,502 $ 67,048 Less: Amount representing imputed interest $ (2,409) (250) $ (2,659) Present Value of minimum lease payments $ 54,137 10,252 $ 64,389 Weighted average discount rate 2% Weighted average remaining term 3.94 years

NOTE 4 - RELATED PARTY TRANSA_2

NOTE 4 - RELATED PARTY TRANSACTIONS: Notes Payable Related Parties (Tables)	9 Months Ended
	Mar. 31, 2022
Tables/Schedules
Notes Payable Related Parties	Date Loan amount in EURO Loan amount converted into USD Interest rate Interest in USD Due March 06, 2015 100,000 110,815 5% 38,202 June 30, 2022 December 12, 2017 25,000 27,704 2% 2,383 on demand January 19, 2018 25,000 27,704 2% 2,326 on demand March 13, 2018 25,000 27,704 2% 2,245 on demand July 16, 2018 25,000 27,704 2% 2,055 on demand September 10, 2018 25,000 27,704 2% 1,970 on demand October 04, 2018 25,000 27,704 2% 1,934 on demand December 27, 2018 25,000 27,704 2% 1,806 on demand January 21, 2019 15,000 16,622 2% 1,061 on demand February 26, 2019 25,000 27,704 2% 1,714 on demand March 20, 2019 25,000 27,704 2% 1,680 on demand April 08, 2019 20,000 22,163 2% 1,321 on demand May 09, 2019 30,000 33,245 2% 1,925 on demand June 21, 2019 30,000 33,245 2% 1,847 on demand September 17, 2019 20,000 22,163 2% 1,125 on demand October 04, 2019 20,000 22,163 2% 1,104 on demand October 30, 2019 20,000 22,163 2% 1,072 on demand January 08, 2020 10,000 11,082 2% 494 on demand February 20, 2020 10,000 11,082 2% 468 on demand March 06, 2020 15,000 16,622 2% 688 on demand April 01, 2020 10,000 11,082 2% 443 on demand May 05, 2020 15,000 16,622 2% 633 on demand June 10, 2020 10,000 11,082 2% 400 on demand July 27, 2020 10,000 11,082 2% 372 on demand September 07, 2020 10,000 11,114 2% 346 on demand September 21, 2020 10,000 11,193 2% 338 on demand October 09, 2020 15,000 16,659 2% 490 on demand December 03, 2020 10,000 10,784 2% 293 on demand January 05, 2021 10,000 10,638 2% 273 on demand February 11, 2021 10,000 10,806 2% 251 on demand March 17, 2021 10,000 11,029 2% 230 on demand July 29, 2021 10,000 11,082 2% 149 on demand October 04, 2021 20,000 22,163 2% 216 on demand December 01, 2021 10,000 11,082 2% 73 on demand Total 675,000 747,114 71,928

NOTE 2 - SUMMARY OF SIGNIFIC_14

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	Mar. 31, 2022
Sangui BioTech GmbH
Equity Method Investment, Ownership Percentage	90.00%

NOTE 2 - SUMMARY OF SIGNIFIC_15

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Foreign Currency Translation: Schedule of Foreign currency rates (Details)	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Year End Rates
Foreign Currency Exchange Rate, Translation			0.902405	0.851250
Average Period Rates
ForeignCurrencyExchangeRateTranslation	0.871273	0.841351

NOTE 2 - SUMMARY OF SIGNIFIC_16

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Going Concern (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021
Details
Accumulated deficit	$ 37,947,171		$ 37,947,171		$ 37,895,315
NET LOSS BEFORE NON-CONTROLLING INTEREST	$ 15,476	$ 738	53,554	$ 151,923
Net Cash Used in Operating Activities			$ 103,119	$ 104,178

NOTE 2 - SUMMARY OF SIGNIFIC_17

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Trade Accounts Receivable (Details) - USD ($)	9 Months Ended	12 Months Ended
	Mar. 31, 2022	Jun. 30, 2021
Details
Accounts Receivable, Allowance for Credit Loss, Writeoff	$ 0	$ 0

NOTE 3 - COMMITMENTS AND CONT_3

NOTE 3 - COMMITMENTS AND CONTINGENCIES (Details)	9 Months Ended
	Mar. 31, 2022
Office
Lessee, Operating Lease, Description	The Company leases office facilities from an unrelated third party at 1,172 Euros per month, which amount includes 187 Euros for sales tax. The office lease contract began in January 2020 and expires June 2026.
Automobile
Lessee, Operating Lease, Description	The Company also leases an automobile under an operating lease. The lease provides for a lease payment of 538 Euros per month that began June 2018 expired May of 2020. The company extended the expired contract until May 2021 and then continued on a month-to-month basis, until a new lease vehicle was available. The monthly leasing rate was 670 Euros for the period from June 2020 to May 2021.
Automobile 2
Lessee, Operating Lease, Description	The company has signed a leasing contract for a new automobile with a term of 36 months with monthly leasing installments of 338 Euros ($375) and an initial deposit of 9,189 Euros ($10,183) in May 2021. The automobile was delivered in August 2021. The leasing contract that expired in May 2021 was continued until the new automobile has been delivered.

NOTE 3 - COMMITMENTS AND CONT_4

NOTE 3 - COMMITMENTS AND CONTINGENCIES: Minimum Lease Payments Under Operating Leases (Details)	9 Months Ended
	Mar. 31, 2022USD ($)
2022	$ 4,341
2023	17,479
2024	17,712
Thereafter	27,516
Total Operating Lease Obligations	67,048
Less: Amount representing imputed interest	(2,659)
Present Value of minimum lease payments	64,389
Office
2022	3,216
2023	12,978
2024	13,211
Thereafter	27,141
Total Operating Lease Obligations	56,546
Less: Amount representing imputed interest	(2,409)
Present Value of minimum lease payments	54,137
Automobile
2022	1,125
2023	4,501
2024	4,501
Thereafter	375
Total Operating Lease Obligations	10,502
Less: Amount representing imputed interest	(250)
Present Value of minimum lease payments	$ 10,252

NOTE 4 - RELATED PARTY TRANSA_3

NOTE 4 - RELATED PARTY TRANSACTIONS: Notes Payable Related Parties (Details) - USD ($)	Mar. 31, 2022	Dec. 01, 2021	Oct. 04, 2021	Jul. 29, 2021	Mar. 17, 2021	Feb. 11, 2021	Jan. 05, 2021	Dec. 03, 2020	Oct. 09, 2020	Sep. 21, 2020	Sep. 07, 2020	Jul. 27, 2020	Jun. 10, 2020	May 05, 2020	Apr. 01, 2020	Mar. 06, 2020	Feb. 20, 2020	Jan. 08, 2020	Oct. 30, 2019	Oct. 04, 2019	Sep. 17, 2019	Jun. 21, 2019	May 09, 2019	Apr. 08, 2019	Mar. 20, 2019	Feb. 26, 2019	Jan. 21, 2019	Dec. 27, 2018	Oct. 04, 2018	Sep. 10, 2018	Jul. 16, 2018	Mar. 13, 2018	Jan. 19, 2018	Dec. 12, 2017	Mar. 06, 2015
Interest rate		2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	5.00%
Due		on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	June 30, 2022
Director
Interest rate	2.00%
Director | Euro Member Countries, Euro
Loan amount in EURO	$ 675,000	$ 10,000	$ 20,000	$ 10,000	$ 10,000	$ 10,000	$ 10,000	$ 10,000	$ 15,000	$ 10,000	$ 10,000	$ 10,000	$ 10,000	$ 15,000	$ 10,000	$ 15,000	$ 10,000	$ 10,000	$ 20,000	$ 20,000	$ 20,000	$ 30,000	$ 30,000	$ 20,000	$ 25,000	$ 25,000	$ 15,000	$ 25,000	$ 25,000	$ 25,000	$ 25,000	$ 25,000	$ 25,000	$ 25,000	$ 100,000
Director | United States dollar (next day) (funds code)
Loan amount converted into USD	747,114	11,082	22,163	11,082	11,029	10,806	10,638	10,784	16,659	11,193	11,114	11,082	11,082	16,622	11,082	16,622	11,082	11,082	22,163	22,163	22,163	33,245	33,245	22,163	27,704	27,704	16,622	27,704	27,704	27,704	27,704	27,704	27,704	27,704	110,815
Interest in USD	$ 71,928	$ 73	$ 216	$ 149	$ 230	$ 251	$ 273	$ 293	$ 490	$ 338	$ 346	$ 372	$ 400	$ 633	$ 443	$ 688	$ 468	$ 494	$ 1,072	$ 1,104	$ 1,125	$ 1,847	$ 1,925	$ 1,321	$ 1,680	$ 1,714	$ 1,061	$ 1,806	$ 1,934	$ 1,970	$ 2,055	$ 2,245	$ 2,326	$ 2,383	$ 38,202

NOTE 4 - RELATED PARTY TRANSA_4

NOTE 4 - RELATED PARTY TRANSACTIONS (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 01, 2021	Oct. 04, 2021	Jul. 29, 2021	Jun. 30, 2021	Mar. 17, 2021	Feb. 11, 2021	Jan. 05, 2021	Dec. 03, 2020	Oct. 09, 2020	Sep. 21, 2020	Sep. 07, 2020	Jul. 27, 2020	Jun. 10, 2020	May 05, 2020	Apr. 01, 2020	Mar. 06, 2020	Feb. 20, 2020	Jan. 08, 2020	Oct. 30, 2019	Oct. 04, 2019	Sep. 17, 2019	Jun. 21, 2019	May 09, 2019	Apr. 08, 2019	Mar. 20, 2019	Feb. 26, 2019	Jan. 21, 2019	Dec. 27, 2018	Oct. 04, 2018	Sep. 10, 2018	Jul. 16, 2018	Mar. 13, 2018	Jan. 19, 2018	Dec. 12, 2017	Mar. 06, 2015
Accrued interest - related party	$ 71,928					$ 62,485
Interest rate			2.00%	2.00%	2.00%		2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	5.00%
Interest Expense	13,981	$ 13,273
Notes Payable	$ 66,489
Director
Interest rate	2.00%
Director | Principal
Accrued interest - related party	$ 44,326
Director | Interest
Accrued interest - related party	$ 71,928

NOTE 5 - CAPITAL STOCK (Details

NOTE 5 - CAPITAL STOCK (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021
Preferred Stock, Shares Authorized	10,000,000		10,000,000		10,000,000
Common Stock, Shares Authorized	250,000,000		250,000,000		250,000,000
Common Stock, Shares, Issued	209,955,598		209,955,598		206,955,598
Common Stock, Shares, Outstanding	209,901,842		209,901,842		206,901,842
Proceeds from common stock issued for cash	$ 16,478		$ 28,345	$ 0
Common stock issued to settle accounts payable	8,435		$ 8,435
Common stock issued to settle accounts payable			383,444
Loss on Settlement on accounts payable	$ 4,254	$ 0	$ 4,254	$ 0
Treasury Stock, Common, Shares	53,756		53,756
Treasury Stock, Value	$ 19,387		$ 19,387
Stock Issuance 1
Common stock issued for cash			1,000,000
Proceeds from common stock issued for cash			$ 11,867
Stock Issuance 2
Common stock issued for cash			1,616,556
Proceeds from common stock issued for cash			$ 16,478